Physician profile
Won T Lee
NPI 1336106921
$5,868.74
in general payments reported to CMS, 2019-2025
26 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $484 · 2021: $1,125 · 2022: $1,707 · 2023: $1,366 · 2024: $52.71 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $718.28 | 2019-2024 | Austedo, Uzedy |
| Abbvie INC. | $563.91 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $558.24 | 2020-2023 | |
| Alkermes, INC. | $529.26 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $462.91 | 2019-2023 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $450.30 | 2019-2023 | Spravato |
| Allergan, INC. | $358.03 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $323.12 | 2019-2023 | Ingrezza |
| Vanda Pharmaceuticals INC. | $223.56 | 2019-2023 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $221.45 | 2019 | |
| Axsome Therapeutics, INC. | $196.76 | 2022-2023 | Auvelity |
| Lundbeck LLC | $180.92 | 2020-2023 | Rexulti |
| Almatica Pharma LLC | $166.01 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $139.25 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $134.93 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $132.62 | 2019-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $128.33 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $72.51 | 2019-2022 | |
| Neuronetics, INC. | $66.53 | 2019-2022 | |
| Tris Pharma INC | $62.46 | 2023 | Dyanavel Xr |
| Indivior INC. | $46.34 | 2019-2021 | |
| Eisai INC. | $39.27 | 2021 | |
| Brainsway USA INC | $36.38 | 2019 | |
| Neos Therapeutics, Lp | $21.75 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.32 | 2022 | |
| Sage Therapeutics, LLC | $17.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Won Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.